Urge to smoke over 52 weeks of abstinence
- 568 Downloads
Cigarette cravings are well documented during the first weeks of smoking abstinence. Treatments focus on helping smokers reduce these acute cravings. Cravings experienced later on are less well understood and may be important when considering treatment duration.
We conducted a longitudinal study of cravings over 52 weeks of smoking abstinence.
Cravings were operationalised as strength of, and time spent with, urges to smoke. These were assessed among 452 smokers quitting with behavioural support but without pharmacotherapies. Individuals maintaining abstinence were assessed at 1, 2, 3, 4, 26 and 52 weeks after quitting (n = 197, 156, 139, 131, 66 and 38, respectively). Abstinence was validated at each assessment by expired carbon monoxide. Time courses were plotted for those abstinent for 52 weeks and for those abstinent up to earlier time points. Correlations were examined between ratings of urges at consecutive time points.
Ratings of strength of urges to smoke followed an exponential decline over 52 weeks of abstinence, but 6 months after quitting 13 % of ex-smokers still reported strong urges. At 12 months, no ex-smokers reported strong urges, although 34 % reported some urges. Strength of urges to smoke after 1, 2, 3 and 4 weeks of abstinence predicted strength of urges at 6 months.
Strength of urges to smoke decline exponentially over time following smoking cessation, though some smokers report strong urges after 6 months of abstinence, and urges are still reported by a third of smokers after 12 months. Relapse prevention treatments may need to target prolonged craving.
KeywordsUrges to smoke Cravings Time course Smoking abstinence
This study was funded by the Wellcome Trust and Cancer Research UK. Dr. Ussher and Professors West and Hajek are members of the UK Centre for Tobacco Control Studies.
Conflict of interest
Professors West and Hajek undertake research and consultancy for companies that develop and manufacture smoking cessation medications. Professor West has a share of a patent in a novel nicotine delivery device. Dr. Beard has received conference funding from Pfizer. The remaining authors declare no conflict of interest.
- Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Patil KD, Rennard SI (1999) The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 28:113–118PubMedCrossRefGoogle Scholar